Search
for
Sort by
Research 31–60 of 120
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Janus kinase inhibitors for alopecia areata
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Alopecia Areata: An Updated Review for 2023
- JAK Inhibitors for Treatment of Alopecia Areata
- Alopecia Areata: Current Treatments and New Directions
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia areata – Current understanding and management
- Baricitinib for the Treatment of Alopecia Areata
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Alopecia – New building blocks
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Janus kinase inhibitors for alopecia areata: A narrative review
- Alopecia areata – Aktuelles Verständnis und Management
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database